Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib

被引：0

作者：

Chun-wei Xu

Wen-xian Wang

Yan-ping Chen

Yu Chen

Wei Liu

Li-hua Zhong

Fang-fang Chen

Wu Zhuang

Zheng-bo Song

Xiao-hui Chen

Yun-jian Huang

Yan-fang Guan

Xin Yi

Tang-feng Lv

Wei-feng Zhu

Jian-ping Lu

Xiao-jiang Wang

Yi Shi

Xian-dong Lin

Gang Chen

Yong Song

机构：

[1] Fujian Cancer Hospital,Department of Pathology

[2] Fujian Medical University Cancer Hospital,Department of Chemotherapy

[3] Zhejiang Cancer Hospital,Department of Medical Oncology

[4] Fujian Cancer Hospital,Department of Thoracic Surgery

[5] Fujian Medical University Cancer Hospital,Department of Respiratory Medicine

[6] Fujian Cancer Hospital,undefined

[7] Fujian Medical University Cancer Hospital,undefined

[8] Geneplus-Beijing,undefined

[9] Jinling Hospital,undefined

来源：

Journal of Translational Medicine | / 16卷

关键词：

NSCLC; ALK; VENTANA IHC; RT-PCR; NGS; Crizotinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
Xing, Puyuan
Wang, Shouzheng
Hao, Xuezhi
Zhang, Tongtong
Li, Junling
ONCOTARGET, 2016, 7 (51) : 84666 - 84674
[32] Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Peter N. Morcos
Eveline Nueesch
Felix Jaminion
Elena Guerini
Joy C. Hsu
Walter Bordogna
Bogdana Balas
Francois Mercier
Cancer Chemotherapy and Pharmacology, 2018, 82 : 129 - 138
[33] Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
Niu, Fei-Yu
Wu, Yi-Long
ONCOTARGETS AND THERAPY, 2015, 8 : 999 - 1007
[34] ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne, Florence
Quere, Gilles
Andrieu-Key, Sophie
Descourt, Renaud
Quintin-Roue, Isabelle
Talagas, Matthieu
Braekeleer, Marc De
Marcorelles, Pascale
Uguen, Arnaud
LUNG CANCER, 2016, 91 : 67 - 69
[35] Crizotinib for ROS1-rearranged non-small cell lung cancer patients
Domblides, Charlotte
Antoine, Martine
Lavole, Armelle
Cadranel, Jacques
Wislez, Marie
BULLETIN DU CANCER, 2017, 104 (04) : 303 - 310
[36] THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
Noma, Daisuke
Sakamoto, Kazuhiro
Ando, Kohei
Amano, Shinya G.
Sudo, Shigeto
Goto, Hideto
Yamakawa, Yasushi
Tsubakihara, Motofumi
Tsuboi, Masahiro
Masuda, Munetaka
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1320 - S1320
[37] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
Passaro, A.
Prelaj, A.
Pochesci, A.
Spitaleri, G.
Rossi, G.
Del Signore, E.
Catania, C.
de Marinis, F.
DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
[38] Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
Liu, Chang
Yu, Hui
Long, Qianqian
Chen, Haiquan
Li, Yuan
Zhao, Weixin
Zhao, Kuaile
Zhu, Zhengfei
Sun, Si
Fan, Min
Chang, Jianhua
Wang, Jialei
FRONTIERS IN ONCOLOGY, 2019, 9
[39] Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique
Nicos, M.
Krawczyk, P.
Wojas-Krawczyk, K.
Bozyk, A.
Jarosz, B.
Sawicki, M.
Trojanowski, T.
Milanowski, J.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12) : 1447 - 1453
[40] Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
Bendaly, Edmond
Dalal, Anand A.
Culver, Kenneth
Galebach, Philip
Bocharova, Iryna
Foster, Rebekah
Sasane, Medha
Macalalad, Alexander R.
Guerin, Annie
ADVANCES IN THERAPY, 2017, 34 (07) : 1673 - 1685

← 1 2 3 4 5 →